Variability of the inhibition by total immunoglobulin ofin vitroautoantibody-mediated erythrophagocytosis by mouse macrophages
Open Access
- 22 May 2006
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 145 (1) , 155-161
- https://doi.org/10.1111/j.1365-2249.2006.03107.x
Abstract
Several autoimmune diseases, mainly autoantibody-mediated, are attenuated by infusion of total IgG (IVIg). The efficacy varies widely from one patient to another. Using an experimental model of in vitro phagocytosis of autoantibody-coated erythrocytes by mouse macrophages, we analysed the possible causes for such a variability. Our results indicated that the efficacy of the phagocytosis inhibition depends upon different factors, such as the isotype and the extent of polymerization of the immunoglobulin used for the treatment as well as the genetic background of the mice and the state of macrophage activation that can be influenced by concomitant viral infection. The development of an in vitro assay for the phagocytic activity of macrophages might improve the selection of patients susceptible to benefit from IVIg treatment.Keywords
This publication has 54 references indexed in Scilit:
- Tetramolecular immune complexes are more efficient than IVIg to prevent antibody‐dependent in vitro and in vivo phagocytosis of blood cellsBritish Journal of Haematology, 2004
- Is there a Role for Interleukin-1 Blockade in Intravenous Immunoglobulin Therapy?Immunological Reviews, 1994
- Observations on the Mode of Action of Normal Immunoglobulin at High DosesImmunological Reviews, 1994
- Monoclonal anti-erythrocyte autoantibodies derived from NZB mice cause autoimmune hemolytic anemia by two distinct pathogenic mechanismsInternational Immunology, 1990
- The concept of anti-idiotypic regulation of selected autoimmune diseases by intravenous immunoglobulinClinical Immunology and Immunopathology, 1989
- Rapid transient reversal of anemia and long-term effects of maintenance intravenous immunoglobulin for autoimmune hemolytic anemia in patients with lymphoproliferative disordersThe American Journal of Medicine, 1988
- The Treatment of Kawasaki Syndrome with Intravenous Gamma GlobulinNew England Journal of Medicine, 1986
- Treatment of Refractory Immune Thrombocytopenic Purpura with an Anti-Fcγ-Receptor AntibodyNew England Journal of Medicine, 1986
- Transient Reversal of Thrombocytopenia in Idiopathic Thrombocytopenic Purpura by High-Dose Intravenous Gamma GlobulinNew England Journal of Medicine, 1982
- HIGH-DOSE INTRAVENOUS GAMMAGLOBULIN FOR IDIOPATHIC THROMBOCYTOPENIC PURPURA IN CHILDHOODThe Lancet, 1981